Alpha Cognition Inc. announced that it has filed a new composition-of-matter patent that secures broad protection for its lead asset, ALPHA-1062, currently under review by the FDA for mild-to-moderate Alzheimer's Disease. The present composition-of-matter patent application is filed for approval with the USPTO and may be extended to pursue protection throughout the world and, if approved, will secure composition-of-matter protection for an oral formulation of ALPHA-1062. The filing was based on novel and unexpected findings in the clinical trial work the company completed and further demonstrates the uniqueness of ALPHA-1062; If approved, the patent will provide protection for ALPHA-1062 into 2044, adding to other patent protection that currently protect ALPHA-1062 through 2042.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.65 CAD | -4.41% | -1.52% | -1.52% |
Apr. 04 | Alpha Cognition's Q4 Comprehensive Loss Widens A Bit From Year Earlier Period | MT |
Apr. 04 | Alpha Cognition Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-1.52% | 71.31M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ACOG Stock
- News Alpha Cognition Inc.
- Alpha Cognition Inc. Files Composition-Of-M Matter Patent